Personal Health  
comments_image Comments

One Company Has Enormous Power in the Breast Cancer 'Market'—and Their Pricey Test Could Be Costing Lives

Angelina Jolie's op-ed about her approach to mitigating breast cancer risk helped a company's stock value rise 4%. Is that what medicine is really about?

Continued from previous page

 
 
Share
 
 
 

Myriad’s patent on the genes  expires in two years, but the Supreme Court’s ruling will set the broader principle going forward. For now, Jolie’s Op-Ed has apparently made Myriad’s stock price  rise 4 percent, its best level in years.

 

Irin Carmon is a staff writer for Salon. Follow her on Twitter at @irincarmon or email her at icarmon@salon.com.

 
See more stories tagged with: